Papers/PMID:35982162
The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.
Scientific reports2022The record
3 findings · 1 compound · 3 endpoints · 3 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
3 findings
cyanocob(III)alamin — no detected effect on alanine aminotransferase
Evidence strength: moderate.FindingNull result“Although serum levels of ALT in the vitamin B12 group decreased significantly, this change did not reach a significant level compared to the placebo group.”
Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 1000 µg cyanocobalamin, one oral tablet daily for 12 weeks
- Population
- Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.2022PMID:3598216210.1038/s41598-022-18195-8Industry fundedPermalink
cyanocob(III)alamin — no detected effect on fasting blood glucose
Evidence strength: moderate.FindingNull result“In the vitamin B12 group, the levels of FBG significantly decreased; however, the between-group comparison revealed a nonsignificant P-value (P = 0.167).”
Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 1000 µg cyanocobalamin, one oral tablet daily for 12 weeks
- Population
- Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.2022PMID:3598216210.1038/s41598-022-18195-8Industry fundedPermalink
cyanocob(III)alamin — no detected effect on malondialdehyde (circulating)
Evidence strength: moderate.FindingNull result“The serum levels of MDA were reduced significantly in the vitamin B12 group; however, this change was not significant compared to the placebo group (Table 4).”
Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 1000 µg cyanocobalamin, one oral tablet daily for 12 weeks
- Population
- Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.2022PMID:3598216210.1038/s41598-022-18195-8Industry fundedPermalink